Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Certified Research Consultants

Neither a doctor nor a teaching hospital

Research payments

$102,172

35 payments

Through program year 2025, Certified Research Consultants is reported as receiving $102,172 in research payments, across 35 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $10,000 9
2024 Research $41,472 17
2023 Research $50,700 9

Breakdown

Who paid Research payments · program years 2023–2025
  1. Pfizer Inc. $80,244 21 payments
  2. AbbVie, Inc. $21,927 14 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 3 Randomized Placebocontrolled Observerblinded Trial to Evaluate the Safety of A 6Valent Ospabased Lyme Disease Vaccine Vla15 in Healthy Children 5 Through 17 Years of Age $80,244 21 payments
  2. A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation $6,812 2 payments
  3. A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects Ages 2 to 5 Years With Functional Constipation $6,803 4 payments
  4. A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation $3,513 1 payment
  5. M21-862 Ph2 6 mo-2 yr old Functional Constipation Study (3051-201-001) $927 1 payment
  6. M21-572 Ph3 Ped FC Trial 2-5 (LIN-MD-68) (3051-303-001) $927 1 payment
  7. LIN-MD-64 Ph3 Ped FC and IBS-C Trial 6-17 (M21-567) $900 1 payment
  8. 3030-202-002 Ph2 Dose Ranging Peds (M21-485) $804 1 payment
  9. A Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Safety and Efficacy Study of Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (FC) With a 24-week Open-label Treatment Extension $541 1 payment
  10. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) with Irritable Bowel Syndrome with Diarrhea (IBS-D) $469 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record